A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections

Lu, Qiong; Zhu, Haihong; Guohua, LI; Qi, Tingting; Ye, Liang-Jun; Teng, Xin-Qi; Qu, Qiang; He, Guo‐Wei; Qu, Jian

doi:10.3389/fmed.2021.620885

Cited by 8 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, MDR P. aeruginosa is one of the most important bacterial pathogens that cause infections with a high mortality rate ( 22 ). Colistin is considered the “last-line” therapy for treating infections caused by MDR Gram-negative pathogens ( 23 ). However, the resistance to colistin is constantly increasing among clinical isolates, including P. aeruginosa .…”

Section: Discussionmentioning

confidence: 99%

Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to Colistin In Vitro and In Vivo

et al. 2023

View full text Add to dashboard Cite

P. aeruginosa is a ubiquitous Gram-negative opportunistic pathogen associated with a wide array of life-threatening acute and chronic infections. However, the improper and excessive use of antibiotics has contributed to the increasing emergence of multidrug-resistant (MDR) P. aeruginosa , even colistin-resistant strains, which presents a major challenge to clinical anti-infection treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to Colistin In Vitro and In Vivo

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Few studies have investigated the microbiological efficacy of PMB for treatment of CR-GNB. 25 Here, we investigated the microbiological clearance rate of the total course of treatment and 7-day microbiological clearance, which were 39.42% and 29.45%, respectively. Our results showed that urinary tract infection and CRAB infection were independent risk factors associated with bacterial clearance following PMB treatment.…”

Section: Discussionmentioning

confidence: 99%

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety

Qu¹,

Qi²,

Qu³

et al. 2022

IDR

Self Cite

View full text Add to dashboard Cite

Background The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness. Methods Patients with CR-GNB infections treated with PMB for more than three days were enrolled in this retrospective study from 1st June 2018 to 30th April 2020. Data were collected on patient characteristics, bacterial culture, and drug-sensitivity test results; anti-infection treatment regimens, particularly details of PMB use; and adverse drug reactions. Clinical and microbiological efficacy, mortality, and safety of PMB-based regimens in CR-GNB infected patients were evaluated. Univariate analysis and multivariate logistic regression analyses were used to assess factors influencing efficacy and mortality. Results A total of 373 CR-GNB strains were cultured from 268 patients. About 41.04% of patients used PMB loading dose of 1.01 (0.84–1.69) mg/kg. Maintenance dose was 0.85 (0.82–1.00) mg/kg q12h. The clinical efficacy rate was 36.57% (98/268), the total bacterial clearance rate of PMB was 39.42%, and the all-cause mortality rate was 33.96%. The adverse drug reaction rate was 19.58%, among which the incidence of renal toxicity was highest (8.21%). Multivariate logistic regression analysis showed that clinical efficacy, bacterial clearance rate, and all-cause mortality were associated with patient-related facts, including mechanical ventilation use, underlying diseases (such as respiratory disease), the type and site of CR-GNB infection, and PMB administration timing and loading dose. Conclusion PMB is a relatively safe and effective antibiotic drug for treatment of critically ill patients with CR-GNB infection; however, PMB use should be subject to guidelines recommendations for early administration, loading administration, and adequate administration, which could help to improve the clinical efficacy, microbiological efficacy, and mortality.

show abstract

“…Tigecycline (TG) and polymyxin B (PB) have become the main and only antibiotics for the treatment of CRKP infections due to their lowest resistance [3]. They are often combined with other antibiotics for more e cacious CRKP treatment, such as carbapenems, cephalosporins, and sulbactam [4][5][6]. Three types of therapies are commonly used.…”

Section: Introductionmentioning

confidence: 99%

Efficacy Comparison of Tigecycline and Polymyxin B Against Carbapenem-Resistant Klebsiella Pneumoniae Infection in Intensive Care Units, a Multicenter Retrospective Study

Zhang¹,

Hu²,

Deng³

et al. 2022

Preprint

View full text Add to dashboard Cite

Aim: To investigate the efficacy of Tigecycline (TG) or polymyxin B(PB) against Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection in ICUs. Method: Electronic medical record systems were used to capture CRKP-infected patients who were treated with TG- or PB-based therapies from ICUs of four academic hospitals in Hunan, China. Propensity-score matching and logistic regression were used to compare efficacy and find prognostic factors.Results: Of the 236 patients, 106 received TG-based therapy (TG), 102 received PB-based therapy (PB), and 28 received a combination of TG and PB (TG+PB). PB group showed higher CRKP clearance (46.6% vs. 22.4%, P = 0.011) and complete bacterial clearance (32.8% vs. 15.5%, P = 0.051) than TG group. CRKP clearance (OR 0.312, 95%CI 0.159-0.612, P= 0.001), longer duration of PB (4-8 vs. > 8 days, OR 2.974, 95%CI 1.297-6.820, P= 0.010), and less vasoactive agents (1-4 vs. 0 days, OR 2.903, 95%CI 1.146-7.352, P= 0.025) were independent protective factors for 30-day mortality. Conclusions: About CRKP treatment in ICUs, PB-based therapy showed better bacterial clearance than TG-based therapy. CRKP clearance, longer duration of PB, and less vasoactive agents were independent protective factors for 30-day mortalit.

show abstract

A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections

Cited by 8 publications

References 34 publications

Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to Colistin In Vitro and In Vivo

Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to Colistin In Vitro and In Vivo

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety

Efficacy Comparison of Tigecycline and Polymyxin B Against Carbapenem-Resistant Klebsiella Pneumoniae Infection in Intensive Care Units, a Multicenter Retrospective Study

Contact Info

Product

Resources

About